医护人员中 mRNA-1273、BNT162b2 和 Ad26.COV2.S 新冠疫苗的抗体反应持久性比较。

Comparison of antibody response durability of mRNA-1273, BNT162b2, and Ad26.COV2.S SARS-CoV-2 vaccines in healthcare workers.

机构信息

Bassett Research Institute, Bassett Medical Center, Cooperstown, 13326, USA.

Department of Internal Medicine, Bassett Medical Center, Cooperstown, 13326, USA.

出版信息

Int J Infect Dis. 2022 Oct;123:183-191. doi: 10.1016/j.ijid.2022.08.022. Epub 2022 Aug 28.

DOI:10.1016/j.ijid.2022.08.022

PMID:36044963

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9420538/

Abstract

OBJECTIVES

There are limited comparative immunologic durability data post COVID-19 vaccinations.

METHODS

Approximately 8.4 months after primary COVID-19 vaccination, 647 healthcare workers completed surveys about COVID-19 vaccinations/infections and blood draws. The groups included participants vaccinated with mRNA-1273 (n = 387), BNT162b2 (n = 212), or Ad26.COV2.S (n = 10) vaccines; unvaccinated participants (n = 10); and participants who received a booster dose (n = 28). The primary outcome was immunoglobin anti-spike titer. Secondary/tertiary outcomes included neutralizing antibodies (enzyme-linked immunosorbent assay-based pseudoneutralization) and vaccine effectiveness (VE). Antibody levels were compared using analysis of variance and linear regression.

RESULTS

Mean age was 49.7 and 75.3% of the participants were female. Baseline variables were balanced except for immunosuppression, previous COVID-19 infection, and post-primary vaccination time. Unadjusted median (interquartile range [IQR]) anti-spike titers (AU/ml) were 1539.5 (876.7-2626.7) for mRNA-1273, 751.2 (422.0-1381.5) for BNT162b2, 451.6 (103.0-2396.7) for Ad26.COV2.S, 113.4 (3.7-194.0) for unvaccinated participants, and 31898.8 (21347.1-45820.1) for participants administered with booster dose (mRNA-1273 vs BNT162b2, P <.001; mRNA-1273, BNT162b2, or boosted vs unvaccinated, P <.006; mRNA-1273, BNT162b2, Ad26.COV2.S, or unvaccinated vs boosted, P <.001). Unadjusted median (IQR) pseudoneutralization was as follows: 90.9% (80.1-95.0) for mRNA-1273, 77.2% (59.1-89.9) for BNT162b2, 57.9% (36.6-95.8) for Ad26.COV2.S, 40.1% (21.7-60.6) for unvaccinated, and 96.4% (96.1-96.6) for participants administered with booster dose (mRNA-1273 vs BNT162b2, P <.001; mRNA-1273, BNT162b2, or boosted vs unvaccinated, P <.028; mRNA-1273, BNT162b2, Ad26.COV2.S, or unvaccinated vs boosted, P <.001). VE was 87-89% for participants administered mRNA-1273 vaccine, BNT162b2 vaccine, and booster dose, and 33% for Ad26.COV2.S (none significantly different).

CONCLUSION

Antibody responses 8.4 months after primary vaccination were significantly higher with mRNA-1273 than those observed with BNT162b2.

摘要

目的

新冠肺炎疫苗接种后，免疫持久性的相关比较数据有限。

方法

大约在初次接种新冠肺炎疫苗 8.4 个月后，647 名医护人员完成了关于新冠肺炎疫苗接种/感染和血液采集的调查。参与者包括接种 mRNA-1273（n=387）、BNT162b2（n=212）或 Ad26.COV2.S（n=10）疫苗的人群；未接种疫苗的参与者（n=10）；以及接受加强针的人群（n=28）。主要结局是免疫球蛋白抗刺突滴度。次要/三级结局包括中和抗体（基于酶联免疫吸附试验的假中和）和疫苗有效性（VE）。使用方差分析和线性回归比较抗体水平。

结果

平均年龄为 49.7 岁，75.3%的参与者为女性。除免疫抑制、既往新冠肺炎感染和初次接种后时间外，基线变量平衡。未调整的中位数（四分位距[IQR]）抗刺突滴度（AU/ml）为：mRNA-1273 为 1539.5（876.7-2626.7），BNT162b2 为 751.2（422.0-1381.5），Ad26.COV2.S 为 451.6（103.0-2396.7），未接种疫苗的参与者为 113.4（3.7-194.0），接种加强针的参与者为 31898.8（21347.1-45820.1）（mRNA-1273 与 BNT162b2 比较，P<.001；mRNA-1273、BNT162b2 或加强针与未接种疫苗者比较，P<.006；mRNA-1273、BNT162b2、Ad26.COV2.S 或未接种疫苗者与加强针比较，P<.001）。未调整的中位数（IQR）假中和率如下：mRNA-1273 为 90.9%（80.1-95.0），BNT162b2 为 77.2%（59.1-89.9），Ad26.COV2.S 为 57.9%（36.6-95.8），未接种疫苗者为 40.1%（21.7-60.6），接种加强针者为 96.4%（96.1-96.6）（mRNA-1273 与 BNT162b2 比较，P<.001；mRNA-1273、BNT162b2 或加强针与未接种疫苗者比较，P<.028；mRNA-1273、BNT162b2、Ad26.COV2.S 或未接种疫苗者与加强针比较，P<.001）。mRNA-1273 疫苗、BNT162b2 疫苗和加强针的 VE 为 87-89%，Ad26.COV2.S 为 33%（均无显著差异）。